(97 days)
The MiroCam® Capsule Endoscope System is intended for visualization of the small bowel mucosa. It may be used as a tool in the detection of abnormalities of the small bowel in adults and children from two years of age.
The Suspected GI Bleeding Indicator (SGIB) is intended to mark frames of the video suspected of containing blood or red areas.
The MiroCam® Capsule Endoscope System is comprised of the following core components:
- MiroCam® Capsule: MC1000-B
- MiroCam® Receiver: MR1100
- Data Cable / Data Belt (Optional): MR1000-D / MR1000-D(M) or MR1000-D(L)
- MiroView™ Software: MiroView™ U, MiroView™ RTV, MiroView™ RTV-i
The general usage workflow of the MiroCam® system is as follows, the MiroCam® capsule captures images of the Gl tract, which are sent via Human Body Communication to sensor pads which are affixed to the patient body. The sensor pads are connected to the receiver by the data cables. The image data is stored on the receiver for the duration of the patient procedure. After removing the receiver set from the patient body, the receiver is connected via USB to the Commercial PC and the image data is uploaded. Following upload, the physician (Gastroenterologist) reviews the patient image data for suspected abnormalities of the small bowel.
The provided text does not contain detailed information about specific acceptance criteria or an exhaustive study proving the device meets those criteria. The 510(k) summary states that "The performance testing are exactly the same as the predicate device (K123428)," implying that the current submission relies on the testing of its predicate device. This usually means that the device is shown to be substantially equivalent to the predicate through similar technological characteristics and equivalent intended use, rather than a new de novo performance study with specific acceptance criteria.
However, based on the structure of a typical 510(k) submission, and the limited information provided, I can infer some aspects and highlight what is missing.
Here's a breakdown of the requested information, indicating where the document provides details and where it is silent:
1. Table of acceptance criteria and the reported device performance
The document does not explicitly state acceptance criteria or provide a table of reported device performance for this specific submission (K140751). It states that its performance testing is "exactly the same as the predicate device (K123428)." This implies that the current device is considered to have met the performance established for its predicate. Without access to K123428's full submission, specific quantitative acceptance criteria cannot be extracted from this text.
The closest to a performance claim is the intended function of the "Suspected GI Bleeding Indicator (SGIB) is intended to mark frames of the video suspected of containing blood or red areas." However, no metrics (e.g., sensitivity, specificity, accuracy) or acceptance criteria (e.g., >90% sensitivity for SGIB detection) are provided for this feature.
2. Sample size used for the test set and the data provenance
The document does not provide details about the sample size for a test set or data provenance for K140751, as it refers back to the predicate device (K123428) for performance testing.
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts
The document does not provide this information for K140751.
4. Adjudication method for the test set
The document does not provide this information for K140751.
5. If a multi-reader, multi-case (MRMC) comparative effectiveness study was done. If so, what was the effect size of how much human readers improve with AI vs without AI assistance
The document does not indicate that an MRMC comparative effectiveness study was done for K140751. The device description mentions "MiroView™ U provides some kinds of Modes and Views to help the user review patient video data quickly and conveniently; however, IntroMedic Co., Ltd. recommends that the doctor review the patient video in the Normal Mode / Single View to prevent from a wrong diagnosis." This statement suggests a recommendation against relying solely on AI-assisted views for diagnosis and doesn't claim an improvement in human reader performance with AI assistance.
6. If a standalone (i.e. algorithm only without human-in-the loop performance) was done
The document does not explicitly present data on standalone algorithm performance for K140751. The "Suspected GI Bleeding Indicator (SGIB)" feature could imply an algorithm-only function, but no performance metrics are given.
7. The type of ground truth used
The document does not provide information on the type of ground truth used for K140751.
8. The sample size for the training set
The document does not provide information on the sample size for any training set for K140751.
9. How the ground truth for the training set was established
The document does not provide information on how ground truth was established for any training set for K140751.
Summary of what is known from the provided text for K140751:
The submission for the MiroCam® Capsule Endoscope System (K140751) states that its "Technological Characteristics" and "Performance Testing" are "exactly the same as the predicate device (K123428)." This means that the current device is deemed substantially equivalent based on its similarity to a previously cleared device, rather than requiring new, detailed performance studies to be included in this specific 510(k) summary.
The only specific "performance" mentioned is the Suspected GI Bleeding Indicator (SGIB), which is "intended to mark frames of the video suspected of containing blood or red areas." However, no quantitative performance metrics (e.g., sensitivity, specificity, accuracy) or acceptance criteria for this feature are provided in the document.
To get the detailed information requested, one would need to access the full 510(k) submission for K123428, which is the predicate device for performance testing.
{0}------------------------------------------------
5. 510(k) Summary
This summary of 510(k) safety and effectiveness information is being submitted in accordance with requirements of 21 CFR Part 807.92.
5.1 Company and Correspondent making the submission
| Name | IntroMedic Co., Ltd. |
|---|---|
| Address | Suite 1104, E&C Venture Dream Tower 6-Cha, 197-28Guro-Dong, Guro-Gu, Seoul, 152-719 Korea |
| Telephone | +82-2-801-9300 |
| Fax | +82-2-801-9330 |
| Contact | JinYoung Lee |
| Internet | http://www.intromedic.com |
5.2 Device
| Proprietary Name | MiroCam® Capsule Endoscope System |
|---|---|
| Common Name | Capsule Imaging System |
| Classification Name | 21 CFR 876.1300 (Product Code NEZ) |
5.3 Predicate Device
| Manufacturer | IntroMedic Co., Ltd. |
|---|---|
| Device | MiroCam® Capsule Endoscope System |
| 510(k) Number | K123428 |
{1}------------------------------------------------
| Manufacturer | Given Imaging Ltd. |
|---|---|
| Device | Given PillCam® Platform with PillCam® SB Capsuleswith PillCam® SensorBelt |
| 510(k) Number | K103088 |
5.4 Description
·
(※ The device description is exactly the same as the predicate device (K123428).)
The MiroCam® Capsule Endoscope System is comprised of the following core components:
- -MiroCam® Capsule: MC1000-B
- MiroCam® Receiver: MR1100 ।
- Data Cable / Data Belt (Optional): MR1000-D / MR1000-D(M) or MR1000-D(L) -
- MiroView™ Software: MiroView™ U, MiroView™ RTV, MiroView™ RTV-i -
The general usage workflow of the MiroCam® system is as follows, the MiroCam® capsule captures images of the Gl tract, which are sent via Human Body Communication to sensor pads which are affixed to the patient body. The sensor pads are connected to the receiver by the data cables. The image data is stored on the receiver for the duration of the patient procedure. After removing the receiver set from the patient body, the receiver is connected via USB to the Commercial PC and the image data is uploaded. Following upload, the physician (Gastroenterologist) reviews the patient image data for suspected abnormalities of the small bowel. The key system components are explained in detail below.
MiroCam® Capsule
Functionally, the MiroCam® captures imaging via a CMOS imaging sensor for at least 12 hours at the rate of 3 images per second. Six white LEDs flash in concert with the imaging sensor. A sensor PCB links the imaging sensor to the two gold electrodes of the capsule, from which a weak current is emitted containing the image data via Human Body Communication technology. The weak current is then passed through the bodily tissue and fluid to be picked up by the sensor pads. Human Body Communications is uni-directional from the capsule to the sensor pads.
Physically, the capsule is 24.5mm in length, and 10.8mm in diameter. The exterior of the
{2}------------------------------------------------
capsule is composed of biocompatible materials, capable of withstanding potential bite forces and exposure to fluids in the GI tract.
MiroCam® Receiver
The image data from the capsule is saved to the MiroCam® Receiver via the sensor pads and data cables. The sensor pads are standard ECG type sensor pads (3M Red Dot), which are affixed to the patient's abdomen according to the location guide. The 9 sensor pads are attached to the 9 leads of the data cable, and the data cable is subsequently attached to the Receiver. The Receiver sits in a shoulder pouch, which is put on the patient for the duration of the procedure. A waist pouch is used to organize the data cables. The Receiver can store images for up to 12 hours. The three indicators on the Receiver are for battery status, initialization status of the receiver, and status of signal receipt from the capsule.
The dimensions of the receiver are 140mm in height, 85mm in width, and 40mm in length. The units weight 350 grams with the battery, which is data cable. The battery is lithium ion, and is unique to the Receiver. The battery is rechargeable, and can be charged by placing in the battery charger provided with the Receiver uses a storage flash for storing the images.
The MiroCam® Receiver has RTV (Real-Time View) function to view a capsule in the body in real time. There are the wire communication method to connect to a Commercial PC by USB cable and the wireless communication method to connect to i-Phone, i-Pad or i-Pod touch by Wifi for RTV.
MiroView™ U
The MiroView™ U helps the user to upload the image data from the Receiver and review the image data with displaying.
MiroView™ U will be deployed as three types of software: MiroView™ Server, MiroView™™ Operator and MiroView™ Client Server PC includes two types of SW: MiroView™ Server and Operator
MiroView™ Server and MiroView™ Operator will be deployed on a Server PC. MiroView™ Client SW will be deployed on reviewer's PCs. 10 Client SWs will be able to connect to one
MiroCam® Capsule Endoscope System, Traditional 510(k)
{3}------------------------------------------------
Server PC via Network (LAN) at a time.
MiroView™ Server has functionalities: Data Storage, PACS connectivity
MiroView™ Operator has functionalities: Receiver Management, Case Management and Account Management
MiroView™ Client has functionalities: List Mode (Case Data Management), Review Mode (Video Display, Image Capture, Annotation Box, etc.), Report Mode (User Comment, Auto Disease Name Check, etc.), Export Mode (JPG, AVI, MiroView™ file format)
MiroView™ U provides some kinds of Modes and Views to help the user review patient video data quickly and conveniently; however, IntroMedic Co., Ltd. recommends that the doctor review the patient video in the Normal Mode / Single View to prevent from a wrong diagnosis.
The features are described below:
- Multi-Data Path (MiroView™ Server) -
- Customizing Print Dialog (MiroView™ Client)
- Data Multi-Language (MiroView™ Client) -
- ODF Report (MiroView™ Client) -
- Data Bag (MiroView™ Client) -
- Finding Setting (Custom Finding) (MiroView™M Client) -
5.5 Indications for Use
The MiroCam® Capsule Endoscope System is intended for visualization of the small bowel mucosa. It may be used as a tool in the detection of abnormalities of the small bowel in adults and children from two years of age.
The Suspected GI Bleeding Indicator (SGIB) is intended to mark frames of the video suspected of containing blood or red areas.
5.6 Technological Characteristics
The technology characteristics are exactly the same as the predicate device (K123428).
MiroCam® Capsule Endoscope System, Traditional 510(k)
{4}------------------------------------------------
- 5.7 Performance Testing
The performance testing are exactly the same as the predicate device (K123428).
5.8 Conclusion
Based on the 510k submission data IntroMedic Co., Ltd. believes that MiroCam® Capsule Endoscope System and the predicate devices selected are substantially equivalent and do not change the fundamental scientific technology and indications for use of the market-cleared devices.
{5}------------------------------------------------
Image /page/5/Picture/1 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo consists of a stylized eagle with three lines representing its wings, and the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged in a circle around the eagle. The text is in all caps and appears to be in a sans-serif font.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
June 30, 2014
Intromedic Co., Ltd. % Jinyoung Lee General Manager Suite 1104 E&C Venture Dream Tower 6-cha 197-28 Guro-dong, Guro-gu Seoul 152-719 Korea
Re: K140751
Trade/Device Name: Mirocam® Capsule Endoscope System Regulation Number: 21 CFR& 876.1300 Regulation Name: Ingestible telemetric gastrointestinal capsule imaging system Regulatory Class: II Product Code: NEZ Dated: May 2, 2014 Received: May 5, 2014
Dear Jinyoung Lee,
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies.
{6}------------------------------------------------
Page 2 - Jinyoung Lee
You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportalProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.
Sincerely yours,
Image /page/6/Picture/6 description: The image shows the name "Benjamin Fisher-S" in a bold, sans-serif font. The letters "FDA" are stacked on top of each other in the middle of the name. The letters "FDA" are outlined and have a textured fill.
Benjamin R. Fisher, Ph.D. Director Division of Reproductive, Gastro-Renal, and Urological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{7}------------------------------------------------
4. Indications for Use
510(k) Number (if known): K140751
Device Name: MiroCam® Capsule Endoscope System
Indications for Use:
The MiroCam® Capsule Endoscope System is intended for visualization of the small bowel mucosa. It may be used as a tool in the detection of abnormalities of the small bowel in adults and children from two years of age.
The suspected GI Bleeding Indicator (SGIB) is intended to mark frames of the video suspected of containing blood or red areas.
Prescription Use (Part 21 CFR 801 Subpart D) AND/OR Over-The-Counter Use (Part 21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTUNUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Benian 2014.06.30
IntroMedic Co., Ltd. MiroCam® Capsule Endoscope System, Traditional 510(k)
§ 876.1300 Ingestible telemetric gastrointestinal capsule imaging system.
(a)
Identification. An ingestible telemetric gastrointestinal capsule imaging system is used for visualization of the small bowel mucosa as an adjunctive tool in the detection of abnormalities of the small bowel. The device captures images of the small bowel with a wireless camera contained in a capsule. This device includes an ingestible capsule (containing a light source, camera, transmitter, and battery), an antenna array, a receiving/recording unit, a data storage device, computer software to process the images, and accessories.(b)
Classification. Class II (special controls). The special control is FDA's guidance, “Class II Special Controls Guidance Document: Ingestible Telemetric Gastrointestinal Capsule Imaging Systems; Final Guidance for Industry and FDA.”